MA
MAH0.STU Mereo BioPharma Group plc
- Market cap
- EUR 40.9M
- P/E
- -
- P/B
- 1.60x
- ROE
- -95.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MAH0.STU undervalued?
Graham numberThe Graham number of Mereo BioPharma Group plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mereo BioPharma Group plc fundamental analysis
No fundamental analysis for Mereo BioPharma Group plc yet.
Mereo BioPharma Group plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the …
Full company profileMereo BioPharma Group plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mereo BioPharma Group plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.5M | 0.00 | 10.0M | 0.00 | 500K | 0.00 |
| Gross Profit | -24.6M | -34.6M | -22.7M | -23.6M | -16.3M | 18.6M | 936K | 7.43M | 0.00 | 367K | - |
| Operating Income | -36.2M | -45.3M | -35.2M | -39.5M | -37.6M | -20.9M | -43.6M | -27.1M | -45.7M | -38.3M | -31.2M |
| EBITDA | - | -46.4M | -34.2M | -34.7M | -159M | 18.9M | -32.7M | -26.1M | -40.8M | -40.5M | -26.2M |
| Net Income | -28.4M | -38.8M | -32.0M | -34.8M | -164M | 12.7M | -34.2M | -29.5M | -43.3M | -41.9M | -27.4M |
| EPS | - | -0.55 | -0.45 | -0.36 | -0.48 | 0.02 | -0.05 | -0.04 | -0.06 | -0.05 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 86.8M | 96.3M | 67.3M | 86.4M | 62.9M | 126M | 88.1M | 66.5M | 76.4M | 45.9M | 34.7M |
| Total Liabilities | 7.51M | 33.9M | 34.5M | 46.2M | 77.9M | 38.4M | 26.2M | 16.0M | 15.4M | 5.00M | 6.06M |
| Shareholders' Equity | 79.3M | 62.5M | 32.8M | 40.3M | -15.0M | 88.0M | 61.9M | 50.5M | 61.0M | 40.9M | 28.7M |
| Cash & Short-term Investments | 53.6M | 50.0M | 25.0M | 16.3M | 23.5M | 94.3M | 56.3M | 57.4M | 69.8M | 41.0M | 30.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.7M | -32.1M | -23.1M | -45.9M | -28.3M | -5.24M | -38.8M | -21.1M | -32.8M | -31.0M | -20.7M |
| Capital Expenditure | 3.47K | 16.0K | 34.0K | 21.0K | 16.0K | 535K | 10.0K | 419K | 699K | 320K | 600K |
| Free Cash Flow | - | -34.4M | -23.2M | -46.0M | -28.4M | -5.77M | -38.8M | -21.6M | -33.5M | -31.3M | -21.3M |
| Ratios | |||||||||||
| ROE | -35.8% | -62.1% | -97.7% | -86.6% | - | 14.5% | -55.3% | -58.3% | -70.9% | -102.4% | -95.8% |
| ROA | -32.7% | -40.3% | -47.6% | -40.3% | -259.9% | 10.1% | -38.8% | -44.3% | -56.6% | -91.2% | -79.1% |
| Net Profit Margin | - | - | - | - | - | 34.9% | - | -294.7% | - | -8,375.6% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Mereo BioPharma Group plc dividends
Mereo BioPharma Group plc has not paid dividends in the last 9 fiscal years.
Who owns Mereo BioPharma Group plc
- Insiders 0.75%
- Institutions 33.70%
- Public & others 65.56%
- Shares outstanding 160M
- Free float 125M
Mereo BioPharma Group plc company profile
- Company name
- Mereo BioPharma Group plc
- Ticker
- MAH0.STU
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- One Cavendish Place, London, United Kingdom, W1G 0QF
- Phone
- 44 33 3023 7300
- Website
- mereobiopharma.com
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Mereo BioPharma Group plc management
9- Dr. Denise Vera Scots-Knight Ph.D.Co-Founder, CEO & Executive Director · born 1959
- Mr. Charles Edward SermonCo-Founder, General Counsel, Business Development & Company Secretary · born 1969
- Ms. Christine Fox CPAChief Financial Officer · born 1981
- Dr. John A. Lewicki Ph.D.Chief Scientific Officer · born 1952
- Ms. Bal LallyVP & Head of HR
- Dr. Jackie ParkinSenior VP & Therapeutic Head · born 1958
- Ms. Alexandra Hughes-WilsonChief of Patient Access & Commercial Planning · born 1971
- Mr. Bo KaraSenior VP and Head of Pharmaceutical Development & CMC
- Ms. Bharti NavsariwalaVP & Head of Regulatory Affairs